Dr Göran A. Ando, former chairman of Novo Nordisk and a Swedish life sciences industry veteran, recently moved back to his home country after over 35 years abroad. He shares his view on Swedish healthcare today, which is striving to continue its strong tradition of collaboration. Although Sweden is struggling to increase the number of clinical trials it hosts, Ando truly believes that the country has vast amounts of potential to become a front-runner in implementing the new generation of therapies and remain one of the best healthcare ecosystems in the world.
The best biotech companies and most successful are those who know exactly what is happening on the ground in their therapeutic area now, whilst in parallel visualizing the market in six to seven years’ time, when their drug is at the commercial stage
